Two patients in a cohort of 391 children with acute lymphoblastic leukemia (ALL) presented with symptomatic eosinophilia. Both patients had a very poor molecular response to initial chemotherapy as assessed by real-time PCR measurement of minimal residual disease (MRD) and were stratified accordingly to the high-risk group to receive more intensive chemotherapy and bone marrow transplantation. One has subsequently relapsed and the hypereosinophilia, which also recurred, was of donor cell origin. The coincidence of two ALL patients with high MRD and hypereosinophilia warranted a review of the literature and a description of their case histories. Both patients are girls who enrolled on the Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG) Phase III clinical trial for children with newly diagnosed acute lymphoblastic leukemiaFANZCHOG Study VIII. In this ongoing trial, 8% of the patients to date have been stratified on the basis of MRD into the high-risk group using the same criteria (MRD45 Â 10
À4
) as the AIEOP-BFM ALL 2000 trial.
The first patient was a previously fit and well 12-year-old girl who presented with a respiratory illness and eosinophilia. Progressive respiratory distress, cardiac failure associated with an apical mass, development of a left calf deep venous thrombosis and escalating eosinophilia to 27.1 Â 10 9 /l led to the diagnosis of hypereosinophilic syndrome/Loeffler syndrome. The patient was commenced on high-dose steroids due to serious clinical deterioration and responded dramatically with a rapid drop in her eosinophil count. A bone marrow examination after 6 days of steroid treatment was nondiagnostic for an underlying clonal disorder. The deep venous thrombosis and cardiac mass/ thrombus were treated with enoxaparin and subsequently with warfarin. The hypereosinophilia recurred after ceasing steroids at 13 weeks and a repeat bone marrow biopsy at 18 weeks confirmed pre-B-cell ALL with 44% lymphoid blasts FCD10, CD19 and CD34-positiveFand 29% eosinophilia. Cytogenetics, including fluorescent in situ hybridization, were again normal. Treatment was commenced according to ANZCHOG Study VIII protocol, which uses AIEOP-BFM 2000 treatment for all patients until day 79. The patient (enrolled as patient 81) appeared to respond well to the induction therapy (prednisolone, vincristine, daunorubicin, L-asparaginase and intrathecal methotrexate) with morphological remission and resolution of the hypereosinophilia. MRD levels were measured using real-time PCR based on two patient-specific T-cell receptor gamma (TCRG) gene rearrangements as described previously 1 and evaluated according to published guidelines. 2 The MRD levels for both markers were 4 Â 10 À2 at day 33 (after induction) and 6 Â 10 À3 at day 79 (after consolidation). Since MRD at day 79 was 45 Â 10 À4 , the patient was stratified to the very high-risk group (three high-risk chemotherapy blocks and transplant). The patient progressed through the intensive high-risk blocks of therapy, modified by the reduction of anthracycline dosage due to the patient's already impaired cardiac function. She underwent a nonmyeloablative transplant (conditioned with cyclophosphamide (CPA) 50 mg kg À1 Â 1 day; fludarabine 40 mg m À2 Â 5 days; 200 cGy total body irradiation single fraction and antithymocyte globulin 12 mg kg À1 Â 3 days) with a male 5/6 major histocompatibility complex-matched unrelated cord blood. Peripheral blood fluorescent in situ hybridization studies demonstrated a progressive increase in donor chimerism with 67, 97 and 100% male cells at days þ 15, þ 22 and þ 42 post-transplant, respectively, and 99% donor cells at 3 months post-transplant. MRD, which had been 1 Â 10 À4 a week before transplant, was negative at both 1.5 and 3 months post-transplant. Grade II-III skin graftversus-host disease occurred early after transplant and responded to a short course of corticosteroid therapy. The cyclosporin was tapered at day 90 and the patient was in morphological remission without eosinophilia or MRD at 6 months posttransplant. At 9 and 12 months post-transplant, the bone marrow was in morphological remission but MRD testing gave a lowpositive signal below the quantifiable range (o 10
). The patient relapsed at 17 months post-stem-cell transplant again with hypereosinophilia. The karyotype of the eosinophils was normal XY, that is, male donor cells, whereas the blasts were XX, that is, female patient cells. The patient responded slowly to reinduction therapy but achieved clinical remission, although still MRD positive, before a second transplant. She received a dual-cord myeloablative transplant (conditioning with 12 Gy total body irradiation; CPA 50 mg Â 1 day; fludarabine 40 mg m À2 Â 5 days and antithymocyte globulin 12 mg kg À1 Â 3; with prophylaxis for graft-versus-host disease with mycophenolate mofetil and cyclosporin). Neutrophil and platelet engraftment were noted on days 16 and 35, respectively. Grade II skin and gut acute graft-versus-host disease was observed that responded to a short course of steroid therapy; 100% engraftment of a single cord unit was documented by day 28 after the dual cord transplant. At 7 months follow-up after transplantation, her bone marrow MRD was negative, and after 17 months she remains in third remission.
The second patient was a 9-year-old girl who presented with hypereosinophilia, high fever and dyspnea associated with the presence of marked reticulonodular pulmonary infiltrates on chest X-ray. A lung biopsy was contemplated but, given the possibility of acute leukemia, the decision was made to proceed to bone marrow biopsy. This confirmed precursor B ALL (CD 10, 19, 22, 34 and 45(dim) positive), with normal cytogenetics and fluorescent in situ hybridization. Marrow was tested for a fibroblast growth factor receptor (FGF-R) rearrangement, but this was not identified. She was enrolled on ANZCHOG Study VIII (patient 314) and responded well clinically to induction therapy, achieving remission and resolution of her eosinophilia. MRD levels were measured using two patient-specific TCRG gene markers (no immunoglobulin-heavy chain marker was available) at day 33 and day 79. The MRD levels were 2 Â 10 À2 at day 33 for both markers and 1 Â 10 À3 and 7 Â 10 À4 at day 79, resulting in her stratification to the high-risk group. She subsequently proceeded through two intensive high-risk blocks of therapy and underwent a human leukocyte antigen identical sibling allogeneic bone marrow transplant with total body irradiation/etoposide conditioning 10 months ago. Donor chimerism studies have been performed on a regular basis post-stem-cell transplant and demonstrated 100% XY donor cells.
The MRD kinetics in both these patients were indicative of a more chemoresistant form of ALL than 90-95% of the 365 patients in the cohort assessed for MRD. After induction (day 33), their MRD corresponded to the fourth and seventh highest percentile of the cohort and to the third and fifth percentile after consolidation at day 79 (Figure 1 ). In comparison with the five patients with Philadelphia-positive ALL in the cohort, the MRD levels in the two patients with hypereosinophilia were higher than three and lower than two Philadelphia-positive patients at these early time points. As their treatments were not modified during the induction/consolidation part of the protocol, it is clear that these two patients have resistant disease, which we presume is linked to hypereosinophilia, perhaps because the elevated eosinophils and the resistance have the same root cause.
The incidence of ALL and hypereosinophilia is rare, given as less than 1%. 3 A review of the literature in English conducted by one of us (ML) found the clinical course described for 52 cases in 44 papers (listed in Supplementary Information). Some 
Figure 1
Minimal residual disease (MRD) kinetics for two patients with acute lymphoblastic leukemia (ALL) and hypereosinophilia compared to the 10th, 50th and 90th percentile MRD levels for ALL patients on the same clinical trial.
Letters to the Editor common features of the patients with combined conditions are presented with cough and/or shortness of breath and findings of cardiomegaly and lung infiltrates, which are evident in one-third to two-thirds of the patients. Survival data were available for 46 of the 52 cases and are summarized in Table 1 . Although it appears that the prognosis for patients with both conditions lags behind patients with ALL alone, the outcomes for these patients seem to have improved over time with advances in antileukemic therapy and supportive care, although caution is needed in interpreting the data, as the numbers are small and the data for patients diagnosed since 2000 do not reflect long-term outcomes. Of the 19 reported causes of death, 5 (26%) were eosinophilia related, 7 (37%) were due to ALL relapses, 5 (26%) were caused by infection and 2 (11%) had infection and ALL. The eosinophilic infiltration of lung and heart tissue can make treatment with anthracyclines difficult as well as lead to both morbidity and mortality.
Two of the patients reported in the literature with ALL and hypereosinophilia had undergone allogeneic stem cell transplantation. 4, 5 One patient received a matched-sibling allogeneic bone marrow transplant and survived to the time of the report. 4 Another patient underwent a sex-mismatched cord blood transplant and then a further allogeneic bone marrow transplant during the course of their treatment but eventually died secondary to disease relapse. 5 Cytogenetic abnormalities were detected in about half (30/52) of the patients with ALL associated with hypereosinophilia. The most common abnormality was the translocation t(5;14) (q31;q32) found in six of them. An important distinction to make is that the chromosomal abnormality was usually found only in the leukemic blasts and that the eosinophils had normal karyotypes in 90% of the cases. This finding is consistent with the hypothesis that eosinophilia is reactive, arising due to high levels of expression of a cytokine by the leukemic cells. In cases of patients with t(5;14), it appears that interleukin 5, interleukin 3 and/or granulocyte-stimulating factor are ectopically overexpressed following juxtaposition of the growth factor gene (on chromosome 5) with the immunoglobulin heavy-chain promoter and enhancer on chromosome 14. Overexpression in some or all of these three growth factors could explain a secondary rise in eosinophils through triggering of the production maturation and survival of the cells. Both of our patients had normal karyotypes but a similar cytokine effect is likely, especially for the first patient in whom the post-transplant eosinophilia was demonstrably from male donor cells after clonal re-expansion of the female patient's leukemia.
A recent publication by Utsunomiya et al. (2007) 6 found that the presence of high eosinophil counts (4500/ml) in adult T-leukemia and lymphoma patients was an independent and unfavorable prognostic indicator. These authors proposed that the small subgroup of patients with hypereosinophilia had underlying elevated interleukin 5, which had shifted their T-helper (Th)1/Th2 balance in favour of a Th2 (humoral) response at the expense of Th1. Thus, in adult T-leukemia and lymphoma patients who are already severely immune-compromised by their disease, a further defect in antitumor response could explain poor prognosis. Although there are differences between adult T-leukemia and lymphoma and precursor B ALL, the same concept could apply.
In conclusion, our findings suggest that patients with ALL and hypereosinophilia have an aggressive rare subtype of this disease, which presents additional challenges of therapy resistance in the face of possible end organ damage secondary to eosinophilia. Regular MRD testing of these patients is recommended to allow careful monitoring of treatment responses to build our knowledge of these patients with unusual and resistant forms of the disease.
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